Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1476-511X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study ; volume:21 ; number:1 ; day:2 ; month:7 ; year:2022 ; pages:1-7 ; date:12.2022
Lipids in health and disease ; 21, Heft 1 (2.7.2022), 1-7, 12.2022

Creator: Kjærgaard, Kasper Aalbæk
Harborg, Sixten
Jensen, Henrik Kjærulf
Borgquist, Signe

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12944-022-01666-2

URN: urn:nbn:de:101:1-2022082220401198804838

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kjærgaard, Kasper Aalbæk
Harborg, Sixten
Jensen, Henrik Kjærulf
Borgquist, Signe
SpringerLink (Online service)

Other Objects (12)

P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia

Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia

Familial Hypercholesterolemia: new therapeutic approaches

Sex Differences in Familial Hypercholesterolemia

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia: Present and Future Management

The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia

Current causes of death in familial hypercholesterolemia

Familial hypercholesterolemia in very young myocardial infarction

Deploying Clinical Decision Support for Familial Hypercholesterolemia

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study

P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia

Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia

Familial Hypercholesterolemia: new therapeutic approaches

Sex Differences in Familial Hypercholesterolemia

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia: Present and Future Management

The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia

Current causes of death in familial hypercholesterolemia

Familial hypercholesterolemia in very young myocardial infarction

Deploying Clinical Decision Support for Familial Hypercholesterolemia

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study

P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia

Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia

Familial Hypercholesterolemia: new therapeutic approaches

Sex Differences in Familial Hypercholesterolemia

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia: Present and Future Management

The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia

Current causes of death in familial hypercholesterolemia

Familial hypercholesterolemia in very young myocardial infarction

Deploying Clinical Decision Support for Familial Hypercholesterolemia

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia

Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia

Familial Hypercholesterolemia: new therapeutic approaches

Sex Differences in Familial Hypercholesterolemia

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia: Present and Future Management

The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia

Current causes of death in familial hypercholesterolemia

Familial hypercholesterolemia in very young myocardial infarction

Deploying Clinical Decision Support for Familial Hypercholesterolemia

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study

P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia

Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia

Familial Hypercholesterolemia: new therapeutic approaches

Sex Differences in Familial Hypercholesterolemia

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia: Present and Future Management

The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia

Current causes of death in familial hypercholesterolemia

Familial hypercholesterolemia in very young myocardial infarction

Deploying Clinical Decision Support for Familial Hypercholesterolemia

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study

P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia

Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia

Familial Hypercholesterolemia: new therapeutic approaches

Sex Differences in Familial Hypercholesterolemia

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia: Present and Future Management

The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia

Current causes of death in familial hypercholesterolemia

Familial hypercholesterolemia in very young myocardial infarction

Deploying Clinical Decision Support for Familial Hypercholesterolemia

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study

Related objects

Reset password